Well, Fairmont Equities recently said early next calender year. They give a pretty positive analysis and confirm that the outlook is excellent. But who knows, the expected bounce in SP after the last report never happened. I have held and accumulated over the last 30 years so in 18 months, one way or another, I will be reducing my holdings. No luggage racks on a hearse.
Results from CSL112, which is currently in Phase III trials, are expected to be released in early calendar year 2024. CSL112 is a human plasma‐derived apolipoprotein A‐I aims to reduce the risk of recurrent cardiovascular events in patients with myocardial infarction in the first 90 days after the index event by increasing cholesterol efflux.
https://fairmontequities.com/is-csl-now-a-long-term-buy/
Fair Value, page-115
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$300.77 |
Change
5.990(2.03%) |
Mkt cap ! $145.3B | |||
| Open | High | Low | Value | Volume |
| $295.29 | $302.30 | $295.20 | $232.9M | 775.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $300.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $300.82 | 2599 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |